Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$5.40 +1.3%	$5.90	$4.65 ▼ $10.24	$89.40M	0.49	72,288 shs	13,210 shs
IPA ImmunoPrecise Antibodies	$0.57 -1.1%	$0.45	$0.27 ▼ $1.14	$25.81M	-0.05	2.12 million shs	64,272 shs
SAVA Cassava Sciences	$2.02 -1.2%	$1.64	$1.15 ▼ $42.20	$97.34M	-2.31	3.00 million shs	247,916 shs
VIRI Virios Therapeutics	$5.70 +8.8%	$4.87	$0.13 ▼ $1.04	$109.77M	1.58	1.05 million shs	130,942 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	-4.82%	-6.65%	-12.62%	-24.72%	-27.97%
IPA ImmunoPrecise Antibodies	+2.87%	+17.42%	+29.76%	+67.31%	-47.80%
SAVA Cassava Sciences	-2.86%	-3.77%	+30.77%	-15.00%	-90.41%
VIRI Virios Therapeutics	0.00%	+6.94%	+1.97%	+21.02%	+2,489.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COYA Coya Therapeutics	2.0194 of 5 stars	3.5	3.0	0.0	0.0	2.6	0.8	0.0
IPA ImmunoPrecise Antibodies	2.8723 of 5 stars	3.5	5.0	0.0	0.0	2.1	0.0	1.3
SAVA Cassava Sciences	3.7837 of 5 stars	3.3	1.0	0.0	4.7	3.3	0.0	1.3
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	3.00	Buy	$17.00	214.81% Upside
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	604.23% Upside
SAVA Cassava Sciences	2.50	Moderate Buy	$54.50	2,604.71% Upside
VIRI Virios Therapeutics	2.50	Moderate Buy	$3.00	-47.37% Downside

Current Analyst Ratings Breakdown

Latest IPA, SAVA, VIRI, and COYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/11/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/1/2025	IPA ImmunoPrecise Antibodies	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$3.00 ➝ $3.00
3/31/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
3/27/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/25/2025	SAVA Cassava Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.00 ➝ $2.00
3/20/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
3/18/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/14/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$3.69M	24.51	N/A	N/A	$2.47 per share	2.19
IPA ImmunoPrecise Antibodies	$24.00M	1.08	N/A	N/A	$0.93 per share	0.61
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.26 per share	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	$0.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$7.99M	-$1.07	N/A	N/A	N/A	N/A	-31.63%	-27.76%	8/11/2025 (Estimated)
IPA ImmunoPrecise Antibodies	-$20.13M	-$1.16	N/A	N/A	N/A	-114.50%	-73.74%	-42.68%	8/4/2025 (Estimated)
SAVA Cassava Sciences	-$97.22M	-$1.50	N/A	N/A	N/A	N/A	-88.05%	-64.98%	8/14/2025 (Estimated)
VIRI Virios Therapeutics	-$5.30M	-$0.27	N/A	N/A	N/A	N/A	-130.33%	-115.00%	8/6/2025 (Estimated)

Latest IPA, SAVA, VIRI, and COYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/8/2025	Q1 2025	SAVA Cassava Sciences	N/A	-$0.48	N/A	-$0.48	N/A	N/A
3/28/2025	Q3 2025	IPA ImmunoPrecise Antibodies	-$0.06	-$0.06	N/A	-$0.46	$6.59 million	$4.23 million
3/18/2025	Q4 2024	COYA Coya Therapeutics	-$0.32	-$0.18	+$0.14	-$0.18	$0.10 million	$0.20 million
3/3/2025	Q4 2024	SAVA Cassava Sciences	-$0.68	-$0.57	+$0.11	-$0.57	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
VIRI Virios Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	15.31	15.31
IPA ImmunoPrecise Antibodies	0.36	1.01	0.85
SAVA Cassava Sciences	N/A	3.55	3.55
VIRI Virios Therapeutics	N/A	7.27	7.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
IPA ImmunoPrecise Antibodies	6.70%
SAVA Cassava Sciences	38.05%
VIRI Virios Therapeutics	9.05%

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	12.00%
IPA ImmunoPrecise Antibodies	6.83%
SAVA Cassava Sciences	2.40%
VIRI Virios Therapeutics	12.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	6	16.73 million	14.70 million	Not Optionable
IPA ImmunoPrecise Antibodies	80	45.77 million	28.94 million	Not Optionable
SAVA Cassava Sciences	30	48.31 million	43.78 million	Optionable
VIRI Virios Therapeutics	5	19.26 million	16.91 million	Optionable

IPA, SAVA, VIRI, and COYA Headlines

Recent News About These Companies

Virios Therapeutics (NASDAQ:VIRI) Stock Price Down 1.5% - Time to Sell?

May 12, 2025 | marketbeat.com

Dogwood Therapeutics Inc (DWTX)

March 16, 2025 | investing.com

Dogwood prices 578,950 shares at $8.26 in registered direct offering

March 13, 2025 | markets.businessinsider.com

Dogwood announces conversion of existing $19.5M in debt to equity

March 12, 2025 | markets.businessinsider.com

DWTX Stock trading resumes

February 11, 2025 | markets.businessinsider.com

Dogwood Therapeutics, Inc. (DWTX)

February 2, 2025 | finance.yahoo.com

DWTX Stock trading halted, volatility trading pause

January 28, 2025 | markets.businessinsider.com

DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth

January 23, 2025 | msn.com

Dogwood announces first patient dosed in Phase 2b trial on Halneuron

January 22, 2025 | markets.businessinsider.com

Polluted communities hold their breath as companies struggle with California’s diesel truck ban

December 10, 2024 | apnews.com

Dogwood Therapeutics faces potential Nasdaq delisting

November 24, 2024 | uk.investing.com

Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue

November 18, 2024 | markets.businessinsider.com

Dogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep Disturbance

November 18, 2024 | markets.businessinsider.com

Inovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News Summary

November 16, 2024 | benzinga.com

DWTX: Phase 2 Long COVID Results Expected Soon

November 12, 2024 | msn.com

Buy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst Confidence

November 10, 2024 | markets.businessinsider.com

Dogwood Therapeutics Reports Q3 2024 Financial Results

November 9, 2024 | markets.businessinsider.com

Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

November 8, 2024 | markets.businessinsider.com

Dogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 31, 2024 | finanznachrichten.de

Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

October 30, 2024 | finance.yahoo.com

A New Chapter for Virios (VIRI): Transforming into Dogwood Therapeutics

October 8, 2024 | bovnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
3 Mid-Cap Stocks Turning Heads in AI, Automation, & Cybersecurity
By Nathan Reiff | May 16, 2025
View 3 Mid-Cap Stocks Turning Heads in AI, Automation, & Cybersecurity
Institutions Skipped the Rally: Where the Money Went
By Gabriel Osorio-Mazilli | May 8, 2025
View Institutions Skipped the Rally: Where the Money Went

IPA, SAVA, VIRI, and COYA Company Descriptions

Coya Therapeutics NASDAQ:COYA

$5.40 +0.07 (+1.31%)

As of 11:50 AM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

ImmunoPrecise Antibodies NASDAQ:IPA

$0.57 -0.01 (-1.08%)

As of 11:50 AM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Cassava Sciences NASDAQ:SAVA

$2.02 -0.03 (-1.23%)

As of 11:51 AM Eastern

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Virios Therapeutics NASDAQ:VIRI

$5.70 +0.46 (+8.78%)

As of 05/27/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time